Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
Royalty Pharma (NASDAQ:RPRX) announced that Henry Fernandez has stepped down from his position as Lead Independent Director on the company's Board of Directors, effective August 13, 2025. Fernandez joined the board in July 2020 and was appointed Lead Independent Director in March 2021.
During his tenure, Fernandez contributed to several company milestones, including the completion of internalization. CEO Pablo Legorreta praised Fernandez's leadership and business expertise, particularly valuable during Royalty Pharma's early years as a public company. The company plans to appoint a new Lead Independent Director in the near future.
Royalty Pharma (NASDAQ:RPRX) ha annunciato che Henry Fernandez ha lasciato il ruolo di Lead Independent Director del Consiglio di Amministrazione, con effetto dal 13 agosto 2025. Fernandez 猫 entrato nel board nel luglio 2020 ed 猫 stato nominato Lead Independent Director nel marzo 2021.
Durante il suo mandato, Fernandez ha contribuito a diversi traguardi aziendali, incluso il completamento dell'internalizzazione. Il CEO Pablo Legorreta ha lodato la sua leadership e competenza imprenditoriale, particolarmente preziose nei primi anni di Royalty Pharma come societ脿 quotata. L'azienda prevede di nominare un nuovo Lead Independent Director a breve.
Royalty Pharma (NASDAQ:RPRX) anunci贸 que Henry Fernandez dej贸 su puesto como Lead Independent Director en la junta directiva de la compa帽铆a, con efecto a partir del 13 de agosto de 2025. Fernandez se incorpor贸 al consejo en julio de 2020 y fue nombrado Lead Independent Director en marzo de 2021.
Durante su mandato, Fernandez contribuy贸 a varios hitos de la compa帽铆a, incluido el cierre del proceso de internalizaci贸n. El director ejecutivo Pablo Legorreta elogi贸 su liderazgo y experiencia empresarial, especialmente valiosos durante los primeros a帽os de Royalty Pharma como empresa cotizada. La compa帽铆a planea designar en breve a un nuevo Lead Independent Director.
Royalty Pharma (NASDAQ:RPRX)电� Henry Fernandez臧� 須岇偓 鞚挫偓須岇潣 靾橃劃 霃呺 鞚挫偓歆侅棎靹� 2025雲� 8鞗� 13鞚�攵�搿� 氍茧煬雮嫟瓿� 氚滍憸頄堨姷雼堧嫟. Fernandez电� 2020雲� 7鞗� 鞚挫偓須岇棎 頃╇頄堨溂氅� 2021雲� 3鞗� 靾橃劃 霃呺 鞚挫偓搿� 鞛勲獏霅橃棃鞀惦媹雼�.
鞛瀯 旮瓣皠 霃欖晥 Fernandez电� 雮措秬頇� 鞕勲毳� 韽暔頃� 鞐煬 須岇偓 欤检殧 靹标臣鞐� 旮办棳頄堨姷雼堧嫟. 斓滉碃瓴届榿鞛� 韺岆笖搿� 霠堦碃霠堩儉电� 攴胳潣 毽崝鞁臣 牍勳雼堨姢 鞝勲靹膘潉 雴掛澊 韽夑皜頄堨溂氅�, 鞚吹鐢 Royalty Pharma臧� 靸侅灔 齑堦赴鞐� 鞛堨棃鞚� 霑� 韸鬼瀳 欷戩殧頄堧嫟瓿� 毵愴枅鞀惦媹雼�. 須岇偓电� 臁半臧� 靸堧鞖� 靾橃劃 霃呺 鞚挫偓毳� 靹犾瀯頃� 瓿勴殟鞛呺媹雼�.
Royalty Pharma (NASDAQ:RPRX) a annonc茅 que Henry Fernandez a quitt茅 son poste de Lead Independent Director au conseil d'administration, avec effet au 13 ao没t 2025. Fernandez a rejoint le conseil en juillet 2020 et a 茅t茅 nomm茅 Lead Independent Director en mars 2021.
Au cours de son mandat, Fernandez a contribu茅 脿 plusieurs 茅tapes importantes de la soci茅t茅, notamment 脿 l'ach猫vement du processus d'internalisation. Le PDG Pablo Legorreta a salu茅 son leadership et son expertise commerciale, particuli猫rement pr茅cieux durant les premi猫res ann茅es de Royalty Pharma en tant que soci茅t茅 cot茅e. L'entreprise pr茅voit de nommer prochainement un nouveau Lead Independent Director.
Royalty Pharma (NASDAQ:RPRX) gab bekannt, dass Henry Fernandez sein Amt als Lead Independent Director im Vorstand mit Wirkung zum 13. August 2025 niedergelegt hat. Fernandez trat dem Vorstand im Juli 2020 bei und wurde im M盲rz 2021 zum Lead Independent Director ernannt.
W盲hrend seiner Amtszeit trug Fernandez zu mehreren Meilensteinen des Unternehmens bei, darunter dem Abschluss der Internalisierung. CEO Pablo Legorreta lobte seine F眉hrungsqualit盲ten und unternehmerische Expertise, die besonders in den fr眉hen Jahren von Royalty Pharma als b枚rsennotiertes Unternehmen wertvoll waren. Das Unternehmen plant, in naher Zukunft einen neuen Lead Independent Director zu ernennen.
- None.
- None.
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 and was unanimously appointed as Lead Independent Director in March 2021.
鈥淲e are tremendously grateful for Henry's contributions to Royalty Pharma over the past five years,鈥� said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. 鈥淗is experience as a seasoned chief executive of a public company together with his exceptional business acumen has been invaluable to Royalty Pharma during our first years as a public company. Henry鈥檚 leadership has helped Royalty Pharma achieve numerous milestones, including the completion of the internalization, and positioned us favorably to drive continued growth.鈥�
鈥淚t has been a privilege to serve on Royalty Pharma鈥檚 Board of Directors,鈥� said Henry Fernandez. "Since Royalty Pharma's IPO in 2020, the company has executed its strategy exceptionally well, solidifying its position as the clear leader in the biopharma royalty market. Looking ahead, I am confident Royalty Pharma will continue to deliver long-term compounding growth and create sustained shareholder value through its unique business model and rigorous investment approach."
The company intends to name a new Lead Independent Director in the near future.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry鈥檚 leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly 鈥� directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma鈥檚 current portfolio includes royalties on more than 35 commercial products, including Vertex鈥檚 Trikafta, GSK鈥檚 Trelegy, Roche鈥檚 Evrysdi, Johnson & Johnson鈥檚 Tremfya, Biogen鈥檚 Tysabri and Spinraza, Servier鈥檚 Voranigo, AbbVie and Johnson & Johnson鈥檚 Imbruvica, Astellas and Pfizer鈥檚 Xtandi, Pfizer鈥檚 Nurtec ODT and Gilead鈥檚 Trodelvy, and 16 development-stage product candidates. For more information, visit .听听听
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
FAQ
When did Henry Fernandez step down from Royalty Pharma's (RPRX) Board of Directors?
How long did Henry Fernandez serve on Royalty Pharma's board?
What position did Henry Fernandez hold at Royalty Pharma (RPRX)?
Who will replace Henry Fernandez as Lead Independent Director at Royalty Pharma?
